In January 2010, Flexion announced deals with four major pharmaceutical partners acquiring rights to four clinical-stage compounds, and gaining investment from the world's biggest pharmaceutical company.
News
January 29, 2010 | press release
Flexion Therapeutics Announces Agreements with Four Major Pharmaceutical Companies
October 16, 2009 | press release
Flexion Therapeutics Raises $33 Million in Series A Financing
Industry and Media Coverage
May 2010 | conference report
Beyond borders biotech report 2010, Ernst&Young (PDF 2.2 MB). Flexion CEO Michael Clayman recently participated in an Ernst & Young biotechnology panel at the 2010 BIO International Convention. Read the perspective Mike provided on "The New Normal" for drug R&D on page 9.
January 29, 2010 | article
Flexion Snags Pfizer Bucks, Three Pharma Deals, For New Drug Model, Xconomy | Boston
January 2010 | article
Flexion Exploits Big Pharma as Discovery Supplier, In Vivo (PDF 197 KB)
October 22, 2009 | blog post
Financings of the Fortnight, The In Vivo Blog
March 2008 | article
A More Rational Approach to New Product Development, Harvard Business Review (PDF 222 KB)
December 2007 | article
Flexion: The In-Licensing Advantage of Cheap Proof-of-Concept, Start-Up (PDF 188 KB)
May 2007 | article
Lilly's Chorus Experiment, In Vivo (PDF 197 KB)
Feb 26, 2007 | article
Lilly Sings a New Tune: Chorus Unit Brings High Efficiency Note, The Pink Sheet (PDF 291 KB)
Stay in the loop
Keep up-to-date with developments at Flexion Therapeutics by signing up for email updates.
Media Inquiries
Julie Walters
Tudor Reilly
Tel: +44 (0) 1494 687860
Mobile: +44 (0) 775 3626967
Email: julie.walters@tudor-reilly.com